N-Acetylcysteine in the prevention of ototoxicity

Kidney Int. 2007 Aug;72(3):231-2. doi: 10.1038/sj.ki.5002299.

Abstract

Prevention of ototoxicity after the administration of aminoglycoside antibiotics has been notably difficult, in particular in patients with chronic kidney disease. Feldman et al. report that oral administration of 600 mg N-acetylcysteine twice daily significantly ameliorates gentamicin-induced ototoxicity in hemodialysis patients. That approach may help to prevent aminoglycoside-induced hearing loss in these high-risk patients in daily practice.

Publication types

  • Comment

MeSH terms

  • Acetylcysteine / administration & dosage
  • Acetylcysteine / adverse effects
  • Acetylcysteine / therapeutic use*
  • Administration, Oral
  • Aminoglycosides / adverse effects
  • Aminoglycosides / therapeutic use
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Antioxidants / administration & dosage
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Bacteremia / prevention & control
  • Gentamicins / adverse effects
  • Gentamicins / therapeutic use
  • Hearing Loss / chemically induced
  • Hearing Loss / prevention & control*
  • Humans
  • Kidney Failure, Chronic / therapy
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Antioxidants
  • Gentamicins
  • Acetylcysteine